Stelios Papadopoulos highlights that hospital IRBs, which are not under FDA jurisdiction, can delay clinical trials by 6-12 months. They often second-guess FDA-approved protocols, creating a significant, decentralized, and often-overlooked hurdle for drug developers.

Many effective drugs that are already developed will not reach patients for years because the clinical trial system is the primary bottleneck. This delay is due to logistical and structural inefficiencies in testing, not a lack of scientific discovery.

A key solution to clinical trial delays is for elite NCI-designated cancer centers to accept each other's IRB approvals. If a protocol is approved by MD Anderson, for example, Fred Hutch should honor it without a redundant review. This would eliminate months from the study startup phase.

The US regulatory regime for early clinical trials is so slow that companies are opting for more efficient systems, like Australia's local IRB-based approval. This offshoring of initial research puts the US at a global competitive disadvantage in generating crucial early data.

Regulators like the FDA are actively encouraging the use of AI to improve clinical trial success rates. However, pharmaceutical companies are hesitant to adopt these innovative methods, fearing that any deviation from traditional processes will lead to costly delays or orders to restart the trial.

The US is losing the biotech race not just at the FDA, but due to slow hospital Institutional Review Boards (IRBs) and contracting. A Phase 1 trial takes four weeks in China, while a simple university survey in the US can take over a year for approval, creating a major competitive disadvantage.

The FDA's initiative to review clinical trial data in real-time, aimed at increasing efficiency, is causing concern among industry professionals. They fear regulators might make premature judgments based on early, messy data, potentially canceling promising programs before they can mature.

The primary bottleneck in U.S. clinical trials is not the FDA's 30-day IND approval process, but the slow, expensive 'nuts and bolts' of site activation. This includes redundant budget negotiations, contract formats, and separate scientific and IRB reviews for the same protocol across multiple institutions.

The FDA's inconsistency and the growing gap between its guidance and actions have made regulatory risk a primary evaluation factor for investors, complicating trial design, causing delays, and raising the cost of capital for biotechs.